TUESDAY, JULY 17, 2018

Abbott improves managing TB and multidrug-resistant TB

Abbott improves managing TB and multidrug-resistance
Abbott improves managing TB and multidrug-resistance | Courtesy of cdc.gov
Abbott Laboratories recently said its RealTime MTB and  RealTime MTB RIF/INH Resistance assays improve the management of tuberculosis and multidrug-resistant TB (MDR-TB).

The Abbott RealTime MTB assay has shown to have a high sensitivity to detecting MTB. It has also proven to be a good aid when physicians are diagnosing TB infections, as samples that have even low bacteria, like culture positive specimens and smear negatives, still show results. This is important because then patients can start their TB treatments right away.

Additionally, Abbott RealTime MTB RIF/INH Resistance assay uses positive MTB samples to detect isoniazid and rifampicin resistance. This allows for faster test results and better workflow efficiency.

TB is an infectious disease that is from a bacteria known as Mycobacterium TB (MTB). The illness is considered a major global health care problem, especially as the number of cases of multidrug-resistant TB cases have continued to increase.

MDR-TB occurs when the TB bacteria shows no response to rifampicin and isoniazid, which are first-line or standard anti-TB that are some of the most powerful of health treatments.

Both of the assays are included in the broad infectious disease test menu that is now on Abbott’s automated m2000 RealTime System. The system also includes HCV viral load, HPV, HBV viral load, CT/NG, HIV-1 qualitative for Early Infant Diagnosis, and HIV- viral load.

Organizations in this Story

Abbott Laboratories

Want to get notified whenever we write about Abbott Laboratories ?
Next time we write about Abbott Laboratories, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.